Table 6 Incidence of breakthrough bleeding during treatment with EE/CMA or EE/DRSP

From: A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial

  EE /CMA
n (%)
EE /DRSP
n (%)
Month 1 8 (9.0) 15 (16.9)
Month 3 8 (9.2) 11 (12.4)
Month 6 0 (0.0) 2 (2.3)
  1. Note: No significant difference between treatment groups